1. Articles in category: Cells and Stem Cells

    1-24 of 235 1 2 3 4 5 6 7 8 9 10 »
    1. Validation of post-induction Curie scores in high risk neuroblastoma. A Children's Oncology Group (COG) and SIOPEN group report on SIOPEN/HR-NBL1.

      Validation of post-induction Curie scores in high risk neuroblastoma. A Children's Oncology Group (COG) and SIOPEN group report on SIOPEN/HR-NBL1.

      J Nucl Med. 2017 Sep 08;:

      Authors: Yanik GA, Parisi MT, Naranjo A, Nadel H, Gelfand MJ, Park JR, Ladenstein RL, Poetschger U, Boubaker A, Valteau-Couanet D, Lambert B, Castellani MR, Bar-Sever Z, Oudoux A, Kaminska A, Kreissman SG, Shulkin BL, Matthay KK

      Read Full Article
      Mentions: Staging SIOPEN COG
    2. Historical time to disease progression and progression-free survival in patients with recurrent/refractory neuroblastoma treated in the modern era on Children's Oncology Group early-phase trials.

      Historical time to disease progression and progression-free survival in patients with recurrent/refractory neuroblastoma treated in the modern era on Children's Oncology Group early-phase trials.

      Cancer. 2017 Sep 08;:

      Authors: London WB, Bagatell R, Weigel BJ, Fox E, Guo D, Van Ryn C, Naranjo A, Park JR

      Read Full Article
      Mentions: COG Refractory MYCN
    3. Prolonged Isotretinoin in Ultra High-Risk Neuroblastoma.

      Prolonged Isotretinoin in Ultra High-Risk Neuroblastoma.

      J Pediatr Hematol Oncol. 2017 Jan;39(1):e33-e35

      Authors: Cash T, Alazraki A, Qayed M, Katzenstein HM

      Abstract Patients with high-risk neuroblastoma remain a therapeutic challenge with significant numbers of patients failing to respond sufficiently to initial therapy. These patients with poor response to induction are considered as ultra high-risk and are in need of novel treatment strategies.

      Read Full Article
      Mentions: Treatment
    4. Retinoic acid postconsolidation therapy for high-risk neuroblastoma patients treated with autologous haematopoietic stem cell transplantation.

      Retinoic acid postconsolidation therapy for high-risk neuroblastoma patients treated with autologous haematopoietic stem cell transplantation.

      Cochrane Database Syst Rev. 2017 Aug 25;8:CD010685

      Authors: Peinemann F, van Dalen EC, Enk H, Berthold F

      Abstract BACKGROUND: Neuroblastoma is a rare malignant disease and mainly affects infants and very young children. The tumours mainly develop in the adrenal medullary tissue, with an abdominal mass as the most common presentation.

      Read Full Article
      Mentions: INRG
    5. Case report: value of gene expression profiling in the diagnosis of atypical neuroblastoma.

      Case report: value of gene expression profiling in the diagnosis of atypical neuroblastoma.

      BMC Res Notes. 2017 Aug 17;10(1):413

      Authors: Harttrampf AC, Chen Q, Jüttner E, Geiger J, Vansant G, Khan J, Kontny U

      Abstract BACKGROUND: Nephroblastoma and neuroblastoma belong to the most common abdominal malignancies in childhood.

      Read Full Article
      Mentions: GPOH Imaging MYCN
    6. Neurological Complications of Childhood Cancer.

      Neurological Complications of Childhood Cancer.

      Semin Pediatr Neurol. 2017 Feb;24(1):60-69

      Authors: Weaver L, Samkari A

      Abstract Though the treatment of pediatric cancers has come a long way, acute and chronic effects of cancer are still affecting the life of many children. These effects may be caused not only by the malignancy itself but also by the interventions used for the purpose of treatment.

      Read Full Article
    7. New research points to potential targeted treatments of neuroblastoma tumours

      New research points to potential targeted treatments of neuroblastoma tumours

      Genetic variations appear to pre-dispose children to developing certain severe forms of neuroblastoma, according to new research by the University of Chicago Medicine.

      The findings lay the groundwork for developing more targeted treatments for...

      Read Full Article
      Mentions: MYCN
    8. Potential for more targeted treatments of neuroblastoma tumors

      Genetic variations appear to pre-dispose children to developing certain severe forms of neuroblastoma, according to new research. The findings lay the groundwork for developing more targeted treatments for particularly deadly variations of the cancer.

      Read Full Article
      Mentions: MYCN
    9. New research points to potential for more targeted treatments of neuroblastoma tumors

      New research points to potential for more targeted treatments of neuroblastoma tumors

      ( University of Chicago Medical Center ) Genetic variations appear to pre-dispose children to developing certain severe forms of neuroblastoma, according to new research by the University of Chicago Medicine. The findings lay the groundwork for developing more targeted treatments for particularly deadly variations of the cancer.

      Read Full Article
      Mentions: MYCN
    10. CFC1 is a cancer stemness-regulating factor in neuroblastoma.

      CFC1 is a cancer stemness-regulating factor in neuroblastoma.

      Oncotarget. 2017 Jun 13;:

      Authors: Chikaraishi K, Takenobu H, Sugino RP, Mukae K, Akter J, Haruta M, Kurosumi M, Endo TA, Koseki H, Shimojo N, Ohira M, Kamijo T

      Abstract BACKGROUND: Despite the use of aggressive therapy, survival rates among high-risk neuroblastoma (NB) patients remain poor. Cancer stem cells (CSCs) are considered to be critically involved in the recurrence and metastasis of NB and are isolated as NB spheres.

      Read Full Article
      Mentions: Metastasis
    11. Late Effects in Pediatric High-risk Neuroblastoma Survivors After Intensive Induction Chemotherapy Followed by Myeloablative Consolidation Chemotherapy and Triple Autologous Stem Cell Transplants.

      Late Effects in Pediatric High-risk Neuroblastoma Survivors After Intensive Induction Chemotherapy Followed by Myeloablative Consolidation Chemotherapy and Triple Autologous Stem Cell Transplants.

      J Pediatr Hematol Oncol. 2017 May 23;:

      Authors: Armstrong AE, Danner-Koptik K, Golden S, Schneiderman J, Kletzel M, Reichek J, Gosiengfiao Y

      Read Full Article
      Mentions: Chemotherapy
    12. Incorporation of high-dose (131)I-metaiodobenzylguanidine treatment into tandem high-dose chemotherapy and autologous stem cell transplantation for high-risk neuroblastoma: results of the SMC NB-2009 study.

      "Incorporation of high-dose 131I-MIBG treatment into tandem HDCT/auto-SCT could reduce short- and long-term toxicities associated with TBI, without jeopardizing the survival rate."

      Read Full Article
    13. Iobenguane I-131 or Crizotinib and Standard Therapy in Treating Younger Patients with Newly-Diagnosed High-Risk Neuroblastoma or Ganglioneuroblastoma

      Phase III

      Treatment

      Not yet active

      365 days to 30 years

      ANBL1531

      NCI-2016-01734, NCT03126916

      This partially randomized phase III trial studies iobenguane I-131 or crizotinib and standard therapy in treating younger patients with newly-diagnosed high-risk neuroblastoma or ganglioneuroblastoma. Radioactive drugs, such as iobenguane I-131, may carry radiation directly to tumor cells and not harm normal cells.

      Read Full Article
      Mentions: Treatment INRG ALK
    14. The Transcription Regulator Krüppel-Like Factor 4 and Its Dual Roles of Oncogene in Glioblastoma and Tumor Suppressor in Neuroblastoma.

      The Transcription Regulator Krüppel-Like Factor 4 and Its Dual Roles of Oncogene in Glioblastoma and Tumor Suppressor in Neuroblastoma.

      For Immunopathol Dis Therap. 2016;7(1-2):127-139

      Authors: Ray SK

      Abstract The Krüppel-like factor 4 (KLF4) gene is located on chromosome 9q31.

      Read Full Article
    15. Anti-cancer stemness and anti-invasive activity of bitter taste receptors, TAS2R8 and TAS2R10, in human neuroblastoma cells.

      Anti-cancer stemness and anti-invasive activity of bitter taste receptors, TAS2R8 and TAS2R10, in human neuroblastoma cells.

      PLoS One. 2017;12(5):e0176851

      Authors: Seo Y, Kim YS, Lee KE, Park TH, Kim Y

      Abstract Neuroblastoma (NB) originates from immature neuronal cells and currently has a poor clinical outcome. NB cells possess cancer stem cells (CSCs) characteristics that facilitate the initiation of a tumor, as well as its metastasis.

      Read Full Article
      Mentions: Metastasis
    16. High-Risk Neuroblastoma with Metastases to Bilateral Kidneys at Diagnosis.

      High-Risk Neuroblastoma with Metastases to Bilateral Kidneys at Diagnosis.

      Case Rep Pediatr. 2017;2017:5375091

      Authors: Yoshikawa T, Tanizawa A, Suzuki K, Ikeda K, Nomura E, Maeda Y, Tanaka N, Yamada K, Sakai Y, Imamura Y, Ohshima Y

      Abstract Renal metastasis at diagnosis with neuroblastoma is rare. We present a 14-month-old boy who was diagnosed with high-risk neuroblastoma with multiple metastases, including bilateral kidneys.

      Read Full Article
      Mentions: Metastasis
    17. Iodine-131-meta-iodobenzylguanidine therapy for patients with newly diagnosed high-risk neuroblastoma.

      Iodine-131-meta-iodobenzylguanidine therapy for patients with newly diagnosed high-risk neuroblastoma.

      Cochrane Database Syst Rev. 2017 Apr 21;4:CD010349

      Authors: Kraal KC, van Dalen EC, Tytgat GA, Van Eck-Smit BL

      Abstract BACKGROUND: Patients with newly diagnosed high-risk (HR) neuroblastoma (NBL) still have a poor outcome, despite multi-modality intensive therapy.

      Read Full Article
      Mentions: MIBG
    18. Iobenguane I-131 or Crizotinib and Standard Therapy in Treating Younger Patients With Newly-Diagnosed High-Risk Neuroblastoma or Ganglioneuroblastoma

      Conditions :   Childhood Ganglioneuroblastoma;   Childhood Neuroblastoma;   NMYC Gene Amplification;   Recurrent Neuroblastoma Interventions :   Biological: Aldesleukin;   Procedure: Autologous Hematopoietic Stem Cell Transplantation;   Drug: Busulfan;   Drug: Carboplatin;   Drug: Cisplatin;   Drug: Crizotinib;   Drug: Cyclophosphamide;   Drug: Dexrazoxane Hydrochloride;   Biological: Dinutuximab;   Drug: Doxorubicin Hydrochloride;   Drug: Etoposide Phosphate;   Radiation: External Beam Radiation Therapy;   Radiation: Iobenguane I-131;   Drug: Isotretinoin;   Other: Laboratory Biomarker Analysis;   Drug: Melphalan;   Other: Pharmacological Study;   Biological: Sargramostim;   Procedure: Therapeutic Conventional Surgery;   Drug: Thiotepa;   Drug: Topotecan Hydrochloride;   Drug: Vincristine Sulfate Sponsors :   Children's Oncology Group;   National Cancer Institute (NCI) Not yet recruiting - verified April 2017

      Read Full Article
    19. Management of Neuroblastoma: ICMR Consensus Document.

      Management of Neuroblastoma: ICMR Consensus Document.

      Indian J Pediatr. 2017 Apr 03;:

      Authors: Bansal D, Totadri S, Chinnaswamy G, Agarwala S, Vora T, Arora B, Prasad M, Kapoor G, Radhakrishnan V, Laskar S, Kaur T, Rath GK, Bakhshi S

      Abstract Neuroblastoma (NBL) is the most common extra-cranial solid tumor in childhood. High-risk NBL is considered challenging and has one of the least favourable outcomes amongst pediatric cancers.

      Read Full Article
      Mentions: Staging Relapse MYCN
    20. Physical and social characteristics and support needs of adult female childhood cancer survivors who underwent hormone replacement therapy.

      Physical and social characteristics and support needs of adult female childhood cancer survivors who underwent hormone replacement therapy.

      Int J Clin Oncol. 2017 Mar 31;:

      Authors: Tomioka A, Maru M, Kashimada K, Sakakibara H

      Abstract BACKGROUND: Female childhood cancer survivors who develop gonadal dysfunction require female hormone replacement therapy (HRT) from puberty until menopause. However, the support provided in such cases has not been studied.

      Read Full Article
    21. Optimization of a Neural Stem-Cell-Mediated Carboxylesterase/Irinotecan Gene Therapy for Metastatic Neuroblastoma.

      Optimization of a Neural Stem-Cell-Mediated Carboxylesterase/Irinotecan Gene Therapy for Metastatic Neuroblastoma.

      Mol Ther Oncolytics. 2017 Mar 17;4:67-76

      Authors: Gutova M, Goldstein L, Metz M, Hovsepyan A, Tsurkan LG, Tirughana R, Tsaturyan L, Annala AJ, Synold TW, Wan Z, Seeger R, Anderson C, Moats RA, Potter PM, Aboody KS

      Read Full Article
    22. HLA-E inhibitor enhances the killing of neuroblastoma stem cells by co-cultured dendritic cells and cytokine-induced killer cells loaded with membrane-based microparticles.

      HLA-E inhibitor enhances the killing of neuroblastoma stem cells by co-cultured dendritic cells and cytokine-induced killer cells loaded with membrane-based microparticles.

      Am J Cancer Res. 2017;7(2):334-345

      Authors: Zhen Z, Yang K, Ye L, You Z, Chen R, Liu Y, He Y

      Read Full Article
    23. Feasibility, toxicity and response of upfront metaiodobenzylguanidine therapy therapy followed by German Pediatric Oncology Group Neuroblastoma 2004 protocol in newly diagnosed stage 4 neuroblastoma patients.

      Feasibility, toxicity and response of upfront metaiodobenzylguanidine therapy therapy followed by German Pediatric Oncology Group Neuroblastoma 2004 protocol in newly diagnosed stage 4 neuroblastoma patients.

      Eur J Cancer. 2017 Mar 19;76:188-196

      Authors: Kraal KC, Bleeker GM, van Eck-Smit BL, van Eijkelenburg NK, Berthold F, van Noesel MM, Caron HN, Tytgat GA

      Read Full Article
      Mentions: GPOH MIBG
    1-24 of 235 1 2 3 4 5 6 7 8 9 10 »
  1. Categories

    1. Research:

      Cancer Cell, Case Report, Cells and Stem Cells, Clinical Research, Conferences, Disease Classification, Drug, Drug Delivery, Drug Resistance, Epigenetics and Epigenomics, General, Genetics, Genomics, Guidelines, Immune Therapy, Induction, Long Term Effects, Low / Intermediate Risk, Nanotechnology, Olfactory Neuroblastoma, Onco-Fertility, Oncogenesis, Other Cancers, Personalized Medicine, Pharma, Pre-Clinical, Prognostics, PubMed, Review, Small Molecules, Surgery, Survivorship, Trials, Tumor Biology, Virotherapy
    2. Business:

      Funding, IP, Pharma
    3. Non-Profit:

      Advocacy, Charity, Events, Foundation, Funding, Human Interest
    4. Press Release:

      Announcement, News, Pharma
    5. General:

      Adolescent and Young Adults, Bioethics, Blog, Burden of Treatment, Children & Families, Diagnosis and Detection, Drug Development, Epidemiology, Imaging, Incidence, Information, News, Overview of the Disease, Pain Control, Palliative Care, Psychosocial, Regulation, Side-Effects, Social, Supportive Care, Treatment
    6. Media:

      Audio, Blogs, Video
  2. Popular Articles

  3. Organizations in the News

    1. (2 articles) COG
    2. (1 articles) SIOPEN
  4. Researches in the News

    1. (2 articles) MYCN
  5. General Informations in the News

    1. (1 articles) Staging
    2. (1 articles) Treatment
  6. Treatments in the News

    1. (1 articles) Refractory
    2. (1 articles) Stem Cell Transplant